Copertina

Outcomes of real‐world initiation of long‐acting injectable cabotegravir and rilpivirine ( LA ‐I CAB + RPV ) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Alexa Elias, Chloé Pasin, Melanie Smuk, Amy Paterson, Chloe M. Orkin
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	HIV Medicine
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV
di: Kyle Ring, et al.
Pubblicazione: (2025)

Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy
di: Tali Faggiano, et al.
Pubblicazione: (2025)

Clinical management of detectable viraemia during CAB / RPV long‐acting therapy: Are really PIs the only exit strategies?
di: P. F. Salvo, et al.
Pubblicazione: (2026)

Editorial comment on: Gender equality in leadership of HIV care cascade clinical trials: A methodological study
di: Chloé Pasin, et al.
Pubblicazione: (2025)

Y181C ‐associated virologic failure during long‐acting injectable cabotegravir/Rilpivirine in a patient engaged in intensive intravenous Chemsex
di: Víctor Asensi, et al.
Pubblicazione: (2026)

Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net)
di: Kyle Ring, et al.
Pubblicazione: (2024)

Long‐acting cabotegravir and rilpivirine in people with HIV and obesity: Real‐world outcomes from the RELATIVITY cohort
di: Jesús Troya, et al.
Pubblicazione: (2026)

Use of long‐acting cabotegravir and rilpivirine in people living with HIV : A prospective observational cohort study
di: Ana Codonal, et al.
Pubblicazione: (2026)

Clinical outcomes of long‐acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real‐world data from the Spanish RELATIVITY cohort
di: Jesús Troya, et al.
Pubblicazione: (2025)

Real‐world use of long‐acting cabotegravir and rilpivirine: 12‐month results of the inJectable Antiretroviral therapy feasiBility Study (JABS)
di: M. John, et al.
Pubblicazione: (2024)

Efficacy of long‐acting cabotegravir plus rilpivirine in viraemic people living with HIV: A systematic review and meta‐analysis
di: Beatrice Barda, et al.
Pubblicazione: (2025)

Commentary on ‘Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net)’
di: Sanjit Sah, et al.
Pubblicazione: (2024)

Comparison of treatment‐emergent resistance‐associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor‐based single‐tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV : A systematic literature review and network meta‐analysis
di: Ishfaq Rashid, et al.
Pubblicazione: (2025)

User‐reported outcomes of long‐acting injectable PrEP with Cabotegravir: Real‐world experience from Milan
di: Angelo Roberto Raccagni, et al.
Pubblicazione: (2025)

Therapeutic failure reported with HIV long‐acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024
di: Kenneth L. McCall, et al.
Pubblicazione: (2024)

Supporting long‐term engagement in HIV clinical care: Learning from the COVID ‐19 pandemic
di: R. Dhairyawan, et al.
Pubblicazione: (2025)

Effectiveness of switching regimen in people living with HIV and persistent low‐level viraemia in the modern antiretroviral treatment era
di: Tommaso Clemente, et al.
Pubblicazione: (2026)

Impact of HBV serological status on HIV virological efficacy of two‐drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir
di: Pierluigi Francesco Salvo, et al.
Pubblicazione: (2025)

Real‐world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV‐1 aged over 50 years who are virologically suppressed
di: C. Piñeiro, et al.
Pubblicazione: (2024)

Transitions in treatment: A systematic review and meta‐aggregation of preferences and barriers in switching from oral to long‐acting injectable antiretroviral therapy among people living with HIV and stakeholders
di: Tiantian Hu, et al.
Pubblicazione: (2025)

Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies
di: C. Katlama, et al.
Pubblicazione: (2024)

Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort study
di: Ricky K. Hsu, et al.
Pubblicazione: (2024)

Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States : Findings from the antiretroviral pregnancy registry
di: William R. Short, et al.
Pubblicazione: (2025)

Physiologically‐based pharmacokinetic modelling of long‐acting injectable cabotegravir and rilpivirine in pregnancy
di: Shakir Atoyebi, et al.
Pubblicazione: (2024)

Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort
di: Inés Suárez‐García, et al.
Pubblicazione: (2025)

A cross‐sectional comparison of the use of frailty assessment tools in older people living with HIV
di: Chloe Knox, et al.
Pubblicazione: (2025)

Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy
di: Vincenzo Malagnino, et al.
Pubblicazione: (2024)

Biomarkers of inflammation and coagulation predict non‐AIDS‐defining events in a prospective cohort of virologically suppressed people living with HIV
di: Maria Saumoy, et al.
Pubblicazione: (2025)

Effects of transition from paediatric to adult HIV care on virological outcomes in sub‐Saharan Africa: A systematic review and meta‐analysis
di: Petra E. Joseph, et al.
Pubblicazione: (2026)

Treatment durability, satisfaction and quality of life in virologically suppressed HIV ‐1 people switching to doravirine: Results from the French study DoraVIH
di: Spire Bruno, et al.
Pubblicazione: (2026)

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies
di: C. Martorell, et al.
Pubblicazione: (2025)

Factors associated with uptake of gynaecological care and cervical cancer screening among women in the Swiss HIV Cohort Study
di: Mailin Waldecker, et al.
Pubblicazione: (2025)

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV : Data from the COMBINE ‐2 study
di: Cristina Mussini, et al.
Pubblicazione: (2026)

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV ‐suppressed individuals: 48 weeks and beyond
di: Tommy Hing‐cheung Tang, et al.
Pubblicazione: (2026)

Breastfeeding in women living with HIV in high‐income countries: It's time to act
di: Daniela Piacentini, et al.
Pubblicazione: (2024)

Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real‐world cohort analysis
di: Gundolf Schuettfort, et al.
Pubblicazione: (2025)

Narrativas posithivas: vulnerabilidade de mulheres ao hiv/aids em relações heterossexuais de conjugalidade
di: Patrícia Chaves do Nascimento
Pubblicazione: (2018)

Exploring the impact of baseline and on‐treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study
di: M. Gartland, et al.
Pubblicazione: (2025)

Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia
di: Ekaterina Ozhmegova, et al.
Pubblicazione: (2024)

Lenacapavir: Patient and healthcare provider perceptions and the potential role for a twice‐yearly injectable HIV treatment
di: Kate Alford, et al.
Pubblicazione: (2024)